Guidance

Collection of data on recurrent and metastatic breast cancer

Steps to outline how to improve breast cancer clinical care, outcomes and experience for patients has been sent in a letter to the NHS.

Applies to England

Documents

Letter to chief trust executives on recurrent and metatastic breast cancer

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dhsc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Letter to GPs on recurrent and metastatic breast cancer

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@dhsc.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

The letter outlines steps to improve breast cancer clinical care, outcomes and experience for patients diagnosed with recurrent or metastatic breast cancer and has been sent to trust chief executives, GPs and breast multidisciplinary teams (MDTs).

This letter contains the following:

  • information on a 6 month pilot study that took place to identify the extent to which information on recurrent and metastatic breast cancer is available through existing mandated NHS data sources and regional cancer registries
  • important steps that breast MDTs, service providers and GPs in England should be taking now to support better collection and improved clinical care for patients with recurrent and metastatic breast cancer
  • information about measures to be incorporated by National Cancer Peer Review from 2013 to support improvements in data collection (through COSD), and in the clinical care provided for this group of patients
  • links to a toolkit aimed at nurses caring for patients with metastatic breast cancer

The aim must be both to obtain better measurement of outcomes from primary breast cancer treatment, and to secure improvements in the multidisciplinary care and outcomes of those with recurrence or metastasis.

Published 22 November 2012